Drug Profile
Ilixadencel - Mendus
Alternative Names: Allogeneic cancer vaccine - Mendus ; COMBIG-DC; Dendritic cell vaccine - Mendus ; INTUVAX-GIST; INTUVAX-HCC; INTUVAX-RCCLatest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Immunicum
- Developer Mendus; Uppsala University
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Gastrointestinal stromal tumours; Liver cancer; Solid tumours
- Preclinical Gastric cancer; Head and neck cancer; Non-small cell lung cancer
- Discontinued Renal cell carcinoma
Most Recent Events
- 22 Dec 2023 Mendus plans a proof-of-concept trial in Soft tissue sarcoma (Intratumoral) in the first half of 2024
- 22 Dec 2023 Discontinued - Phase-II for Renal cell carcinoma (Combination therapy, Metastatic disease) in France, Hungary, Latvia, Poland, Spain, United Kingdom, Czech Republic, USA and Sweden (Intratumoural)
- 22 Dec 2023 Final efficacy data from the phase-II MERECA trial in Renal cell carcinoma released by Mendus